Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Pelthos Therapeutics Inc.

PTHS

Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.

Last trade $6.86
Day change -$0.29 (-4.06%)
Day range $6.74 – $7.18
Volume 62,909
Market cap $28M

Open XASE

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$28.1M
Price / earnings
—
Price / book
-4.54×
Price / sales
0.55×
EV / sales
1.48×
EV / EBITDA
-1.62×

Profitability

Earnings per share
-$19.86
Return on assets
-60.59%
Return on equity
1,261.7%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-10.55×
Current ratio
1.78×
Quick ratio
1.1×
Cash ratio
0.56×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$32.56M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PTHS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025
Revenue$15.4M$15.6M$10.91M$9.39M$7.41M
Cost of revenue$1.66M$3.61M$1.67M$1.67M$2.32M
Gross profit$13.73M$11.99M$9.23M$7.72M$5.09M
Selling, general and administrative$18.85M$27.67M$21.1M$18.47M$18.38M
Research and development$1.02M$600K$186K$374K$145K
Total operating expenses$23.43M$29.32M$22.32M$19.72M$20.45M
Operating income-$9.69M-$17.32M-$13.09M-$12M-$15.36M
Interest expense-$2.27M-$2.39M-$2.35M-$1.31M-$1.35M
Income before taxes-$7.9M-$23.42M-$25.07M-$28.59M-$16.7M
Income taxes$0$0$0-$6.92M-$465K
Net income-$7.9M-$23.42M-$25.07M-$21.66M-$16.24M
Net income attributable to common shareholders-$7.9M-$23.42M-$25.07M-$21.66M-$16.24M
EBITDA-$8.36M-$16M-$11.59M-$10.79M-$14.29M
Basic earnings per share-$2.04-$6.62-$7.57-$6.78-$5.30
Diluted earnings per share-$2.04-$6.62-$7.57-$6.78-$5.30

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Pelthos Therapeutics Inc. (PTHS) Reports Q3 Loss, Lags Revenue Estimates

Pelthos Therapeutics reported a Q3 loss of $3.09 per share, missing consensus estimates of $2.83 loss, and posted revenues of $15.4 million, falling 15.34% short of expectations. Despite the miss, the company showed improvement from a year-ago loss of $5.3 per share. The stock has declined 69.7% year-to-date while the S&P 500 gained 11.3%. Zacks assigned the stock a Rank #2 (Buy) rating based on favorable estimate revision trends ahead of the earnings release.

GlobeNewswire Inc.

Pelthos Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update

Pelthos Therapeutics reported strong Q3 2026 results with Zelsuvmi net product revenue reaching $15.2 million, up 114% year-over-year. The company announced a definitive merger agreement with Castle Creek Biosciences to create a diversified biotechnology company focused on dermatological and pediatric diseases, combining Pelthos' three FDA-approved products with Castle Creek's late-stage gene therapy candidate D-Fi for dystrophic epidermolysis bullosa.

Zacks Investment Research

Alvotech (ALVO) Reports Q3 Loss, Lags Revenue Estimates

Alvotech reported a quarterly loss of $0.03 per share, significantly worse than the consensus estimate of $0.01 loss, representing a -200% earnings surprise. Revenue of $111.56 million also missed estimates by 18.62%. The stock has underperformed the S&P 500 by 14.8% year-to-date and carries a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends.

Zacks Investment Research

Myriad Genetics (MYGN) Reports Q3 Loss, Beats Revenue Estimates

Myriad Genetics (MYGN) reported a quarterly loss of $0.11 per share, beating consensus estimates of $0.17 loss, representing a 35.29% earnings surprise. Revenue of $202.7 million exceeded estimates by 7.48%, though down slightly year-over-year. The stock has underperformed the S&P 500 by 12.4% this year. Despite mixed performance, the company maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends, with the Medical - Biomedical and Genetics industry ranking in the top 45% of sectors.

GlobeNewswire Inc.

Pelthos Therapeutics Announces 2026 Annual Meeting of Stockholders

Pelthos Therapeutics Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on September 29, 2026. The meeting date represents a change of more than 30 days from the 2025 Annual Meeting anniversary, with stockholder proposals due by August 3, 2026. The company is a commercial-stage biopharmaceutical firm focused on cutaneous infectious disease products.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.